CCRF-CEM Electroporation Kit (CML Leukemia Cells)

Description

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Electroporation Kit for CCRF-CEM Cells (CML Leukemia Cells, CCL-119)

• Electroporation Kit include: electroporation buffer + buffer-specific optimized electroporation protocols
• Preoptimized electroporation protocols are provided for delivery of plasmids (DNA), siRNA, mRNA, and proteins
• Proprietary electroporation buffer formulation mimics cellular cytoplasm composition (superior electropore resealing)
• Certified RNAse- and DNAse-free electroporation buffer
•  Effective electroporation delivery and high cell viability provides reproducible electroporation results
• High cell viability and superior cell recovery rates
• Electroporation protocols are provided with with the purchase of the Electroporation Kit
• UPC/GTIN/EAN: 860002089748
• Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Electroporation Buffer:
4 mL of electroporation buffer is sufficient for 20 reactions using standard 0.2 cm elecrtoporation cuvette
30 mL of electroporation buffer is sufficient for 150 reactions using standard 0.2 cm elecrtoporation cuvette

Electroporation Efficiency:
Electroporation kit provides 80-95% delivery efficiency of siRNA. Electroporation efficiency was determined by qRT-PCR.

Electroporation Protocol and SDS:
Electroporation protocols are provided with the purchase of the Electroporation Kit
Download SDS: [PDF]

CCRF-CEM Cell Line:
The CCRF-CEM cell line was established in 1964 from the peripheral blood of a 4-year-old Caucasian female who suffered from acute lymphoblastic leukemia. These tumorigenic cells exhibit lymphoblast morphology and a T lymphoblast cell type. CCRF-CEM cells positively express CD3 – CD7 antigens, except for CD6. These cells could be useful for transfection experiments to study leukemia. CCRFCEM cells are a human T-cell leukemia cell line that was originally isolated from the peripheral blood of a patient with acute lymphoblastic leukemia. These cells are commonly used as a model system to study the mechanisms underlying T-cell leukemia and to screen potential anti-cancer drugs. CCRF-CEM cells have been extensively studied and characterized, and they are known to exhibit many of the features of T-cell leukemia cells, including rapid proliferation, high levels of cytokine production, and the expression of T-cell surface markers. Researchers use CCRF-CEM cells to investigate the molecular pathways that drive the development and progression of T-cell leukemia, as well as to test the efficacy of potential drugs that may be used to treat the disease. CCRF-CEM cells are a valuable tool in the study of T-cell leukemia and have contributed to advances in our understanding of the disease and the development of new treatments.

Mutations:

Data:

Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, elecroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides safety and efficacy preclinical research services. GLP-compliant studies for IND applications, and drug development, including over 90 in-house validated xenograft models, safety toxicology, etc (visit AltogenLabs.com).

Volume Options:

• 4 ml (Catalog #6559)
• 30 ml (Catalog #6560)

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.